Citadel Advisors’s LakeShore Biopharma LSB Stock Holding History

Citadel Advisors’s Portfolio LSB Stock Details LSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,963	Closed	-$15.3K	–	14400
2025 Q2	$15.3K	Buy	14,963 +4,377	+41%	+$5.5K	﹤0.01%	12155
2025 Q1	$25.6K	Buy	+10,586	New	+$26.2K	﹤0.01%	12952
2024 Q3	–	Sell	-4,068	Closed	-$26.4K	–	15448
2024 Q2	$26.4K	Buy	+4,068	New	+$33.3K	﹤0.01%	12393
2024 Q1	–	Sell	-4,286	Closed	-$23.1K	–	15575
2023 Q4	$23.1K	Buy	+4,286	New	+$24.7K	﹤0.01%	12500

Other funds holding LSB

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citadel Advisors's LSB Position: Q3 2025 in Review

Citadel Advisors sold out of LakeShore Biopharma (LSB) in Q3 2025, closing a stake of 14,963 shares — an estimated $15.3K sold.

Citadel Advisors first reported a position in LSB in Q4 2023 and held it in 4 quarters. The position peaked at $26.4K in Q2 2024. 1 fund tracked by Wall St. Rank holds LSB as of Q3 2025.

Citadel Advisors reported no remaining LakeShore Biopharma position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 14,963 LakeShore Biopharma shares in Q3 2025, an estimated $15.3K.
Citadel Advisors first reported a position in LakeShore Biopharma in Q4 2023 and held it in 4 quarters.
Citadel Advisors's LakeShore Biopharma position peaked at $26.4K in Q2 2024.
1 fund tracked by Wall St. Rank held LakeShore Biopharma as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.